FORM D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Temporary FORM D

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D. SECTION 4(6), AND/OR UNIFORM LIMITED OFFERING EXEMPTION

OMB NUMBER: 3235-0076 Expires: January 31, 2009 Estimated average burden hours per response......4.00

OMB APPROVAL

Name of Offering (check if this is an amendment and name has changed, and indicate change.)

Common Stock

Filing Under (Check box(es) that apply):

☐ Rule 504 Type of Filing: New Filing Amendment

□ Rule 505

■ Rule 506 □ Section 4(6) □ ULOE

8±0 Mall Processing Section

JUUL E / WEL

Weshington. DC

A. BASIC IDENTIFICATION DATA

1. Enter the information requested about the issuer

Name of Issuer (check if this is an amendment and name has changed, and indicate change.)

Alseres Pharmaceuticals, Inc.

Address of Executive Offices (Number and Street, City, State, Zip Code)

239 South Street, Hopkinton, MA 01748

Address of Principal Business Operations (if

different from Executive Offices)

Telephone Number (Including Area Code)

508-497-2360

(Number and Street, City, State, Zip Code)

Telephone Number (Including Area Code)

Brief Description of Business:

development stage biotechnology company engaged in the research and development of novel therapeutic and diagnostic solutions for central nervous system diseases and cancer.

Type of Business Organization

 corporation □ business trust □ limited partnership, already formed

□ limited partnership, to be formed

Jurisdiction of Incorporation or Organization; (Enter two-letter U.S. Postal Service abbreviation for State;

Month Year

Actual or Estimated Date of Incorporation or Organization 10 ■ Actual □ Estimated

CN for Canada; FN for other foreign jurisdiction)

O other (please specify)

DE

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 USC 77d(6).

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

When to File: U.S. Securities and Exchange Commission, 100 F Street, N.E., Washington, D.C. 20549.

Copies Required: Two (2) copies of this notice must be filed with the SEC, one of which must be manually signed. The copy not manually signed must be a photocopy of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State: This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made, If a state requires a payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

		A. BASIC IDENT	IFICATION DATA			
 Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. 						
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	■ Executive Officer	■ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
Savas, Peter G.		•				
Business or Residence Address	(Number and S	Street, City, State, Zip Co	ode)		·····	
		•	,			
c/o Alseres Pharmaceuticals, Inc., 239 S Check Box(es) that Apply:						
Full Name (Last name first, if individual)	□ Promoter	☐ Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner	
run Name (Last hame thst, it muvidua)						
Pykett, Mark J.				·····		
Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)			
c/o Alseres Pharmaceuticals, Inc., 239 S	outh Street. Ho	nkinton, MA 01748				
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
D. 1. 1/2		•		,		
Rice, Jr., Kenneth L. Business or Residence Address	(Number and S	treet, City, State, Zip Co.	te)			
Dustileds of Pediatrice Fiduless	(Transcraine 5	noci, ony, biato, zap co	30)			
c/o Alseres Pharmaceuticals, Inc., 239 S	outh Street, Ho					
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
Langer, Robert						
Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)			
c/o Alseres Pharmaceuticals, Inc., 239 S	auth Straat Ua	ntinton MA 01749				
Check Box(es) that Apply:	□ Promoter	□ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)		D Deliciteiai Owitei	B Executive Officer	- Director	Concin and of managing father	
Mullen, Michael J. Business or Residence Address	Olumbar and S	Stand City State 7in Co	4-1			
business of Residence Address	(Number and 2	Street, City, State, Zip Co	uc)			
c/o Alseres Pharmaceuticals, Inc., 239 S	outh Street, Ho	pkinton, MA 01748				
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
Preston, John T.						
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)			
of Alexan Division of the 120 C		11				
c/o Alseres Pharmaceuticals, Inc., 239 Se Check Box(es) that Apply:	Promoter		☐ Executive Officer	- Di-notos	Commission Managine Partner	
Full Name (Last name first, if individual)	L Promoter	☐ Beneficial Owner	□ Executive Officer	■ Director	☐ General and/or Managing Partner	
,					•	
Guinness, William L.S.	- AL - L	g: a a a			·	
Business or Residence Address	(Number and	Street, City, State, Zip Co	xie)		•	
c/o Alseres Pharmaceuticals, Inc., 239 Se	outh Street, Ho	pkinton, MA 01748				
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	O General and/or Managing Partner	
Full Name (Last name first, if individual)						
Brem, Henry						
Business or Residence Address	(Number and S	treet, City, State, Zip Co	de)			
of Alama Dhama at 1 to 200 C			-			
c/o Alseres Pharmaceuticals, Inc., 239 Se	puin Street, Ho	pkinton, MA U1748				

		A. BASIC IDENI	IFICATION DATA		
2. Enter the information requested for t • Each promoter of the issuer, if • Each beneficial owner having t • Each executive officer and dire • Each general and managing par	the issuer has be the power to vot extor of corporat	e or dispose, or direct the e issuers and of corporate	vote or disposition of, 10		lass of equity securities of the issuer; thip issuers; and
Check Box(es) that Apply:	□ Promoter	□ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)		<u></u>	·	<u> </u>	
Parkin Com B					
Frashier, Gary E. Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)		
Dushings of Residence Reduces	(Number and	onice, only, onle, sup or	40)		
c/o Alseres Pharmaceuticals, Inc., 239 S	outh Street, Ho	pkinton, MA 01748			
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Gipson, Robert L.					
Business or Residence Address	(Number and S	treet, City, State, Zip Co	le)		
				•	
c/o Ingalls & Snyder LLC, 61 Broadway Check Box(es) that Apply:			-r : 00	= D:	
Full Name (Last name first, if individual)	□ Promoter	■ Beneficial Owner	□Executive Officer	☐ Director	☐ General and/or Managing Partner
run Name (Last name mst, ii individual)					•
Gipson, Thomas L.					
Business or Residence Address	(Number and S	treet, City, State, Zip Coo	le)		
c/o Ingalls & Snyder LLC, 61 Broadway	v Naw Vork N	V 10006			
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)			B 2.1.1941.19 0 1.1.1941	<u> </u>	
Ingalls & Snyder LLC					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ae)		
61 Broadway, New York, NY 10006					
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Incelle & Sunday Value Destroys I D					
Ingalls & Snyder Value Partners, LP Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)		
	(1.41110-1-410-1	5.1 doi, 0.15, 5.200, 2.1p 0.	,		
61 Broadway, New York, NY 10006					
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Koenig, Arthur					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
		D - 2 4 400 - 2			
c/o Duferco Steel Inc., Metro Park Sout Check Box(es) that Apply:				- 0'	
Full Name (Last name first, if individual)	☐ Promoter	☐ Beneficial Owner	□ Executive Officer	☐ Director	☐ General and/or Managing Partner
i on ivanie (Last name mst, ii imividual)					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		

	B. INFORMATION ABOUT OFFERING	· · · · · · · · · · · · · · · · · · ·	
		Yes	No
1.	Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?		•
2.	What is the minimum investment that will be accepted from any individual?	\$ <u>n/a</u>	
		Yes	No
3.	Does the offering permit joint ownership of a single unit?	•	0
4.	Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.		
Full Non-	Name (Last name first, if individual)		
	iness or Residence Address (Number and Street, City, State, Zip Code)		· · · · · · · · · · · · · · · · · · ·
Dusi	mess of residence Address (rumber and Street, City, State, Zip Code)		
Nam	ne of Associated Broker or Dealer		
<u> </u>	•		
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers (Check "All States" or check individual States)	All States	
_ [1	AL] _(AK) _(AZ) _(AR) _(CA) _(CO) _(CT) _(DE) _(DC) _(FL) _(GA) IL] _(IN) _(IA) _(KS) _(KY) _(LA) _(ME) _(MD) _(MA) _(MI) _(MN) MT] _(NE) _(NV) _(NH) _(NJ) _(NM) _(NY) _(NC) _(ND) _(OH) _(OK)	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]
Fuli	name (Last name first, if individual)		
Busi	iness or Residence Address (Number and Street, City, State, Zip Code)	<u>. </u>	
Nam	ne of Associated Broker or Dealer	•	
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers		
	(Check "All States" or check individual States)	All States	
[4] [1] [1] [1]	IL] _ [IN] _ [IA] _ [KS] _ [KY] _ (LA) _ [ME] _ [MD] _ [MA] _ [MI] _ [MN] MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]
Full	Name (Last name first, if individual)		
Busi	iness or Residence Address (Number and Street, City, State, Zip Code)	-	
Nam	ne of Associated Broker or Dealer		
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers	·•	
	(Check "All States" or check individual States)	Ail States	
4]_ 1] 1] 1]	AL} _ [AK] _ [AZ] _ [AR] _ [CA] _ [CO] _ [CT] _ [DE] _ [DC] _ [FL] _ [GA] IL] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MN] MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box pand indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	Aggregate Offering Price	Amount Already Sold
	Type of Security		
	Debt	\$	\$
	Equity	\$ <u>1,456,522</u>	\$ 1,456,522
	■ Common □ Preferred		
	Convertible Securities (including warrants)	\$	S
	Partnership Interests	s	\$
	Other (Specify)	s	\$
	Total	\$1,456,522	\$1,456,522
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number of Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	!	\$ <u>1,456,522</u>
	Non-accredited Investors		s
	Total (for filings under Rule 504 only)		\$
	Answer also in Appendix, Column 4, if filing under ULOE		<u> </u>
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C – Question 1.	Type of Security	Doliar Amount Sold
	Type of offering		\$
	Rule 505		
	Regulation A		S
	Rule 504		\$
	Total		\$
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees	D	s
	Printing and Engraving Costs	П	s
	Legal Fees	-	\$ 20,000
	Accounting Fees	-	•
	•		• <u></u>
	Engineering Fees		\$
	Sales Commissions (specify finders' fees separately)	0	s
	Other Expenses (identify)	a	2
	Total		\$ 20,000

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

 b. Enter the difference between the aggregate offering price given in response to Part C - Question l and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer." 				\$_1,436,522		
5.	for each of the purposes shown. If the and check the box to the left of the esti	ted gross proceeds to the issuer used or proposed to amount for any purpose is not known, furnish an est mate. The total of the payments listed must equal that the forth in response to Part C - Question 4.b above.	timate			
				Payments to Officers, Directors, & Affiliates		Payments To Others
	Salaries and fees		0	s	٥	s
	Purchase of real estate		o	s	. 0	\$
	Purchase, rental or leasing and installat	ion of machinery and equipment	0	\$	0	\$
	Construction or leasing of plant building	gs and facilities		\$. 0	s
	Acquisition of other business (including that may be used in exchange for the as	g the value of securities involved in this offering sets or securities of another issuer pursuant to a				
	merger)		0	\$	O	s
	Repayment of indebtedness		0	s	0	s
	Working capital		0	5		S 1.436.522
	Other (specify):		0	s		\$
						•
	(1) (1) (1) (1) (1) (1) (1) (1) (1) (1)		,	s		\$
	Column Totals	***************************************	•	s		\$ <u>1,436,522</u>
	Total Payments Listed (column totals added)			· = \$_1 ,	136,522	
						
•	•	D. FEDERAL SIGNATUR	RE			-
n w	essuer has duly caused this notice to be sindertaking by the issuer to furnish to the accredited investor pursuant to paragraph	gned by the undersigned duly authorized person. If U.S. Securities and Exchange Commission, upon w (b)(2) of Rule 502.	f this notice	is filed under Rule 505, the st of its staff, the information	following furnished	signature constitutes I by the issuer to any
suc	r (Print or Type)	Signature		Date		
Ise	es Pharmaceuticals, Inc.		~	January 15, 2009	•	
am	e of Signer (Print or Type)	Title of Signer (Print or Type)				

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

